Evidence mapPaperPMID 34452239Full record

ArticlePharmaceutics2021

Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.

Wafaa Alabsi, Maria F Acosta, Fahad A Al-Obeidi, Meredith Hay, Robin Polt, Heidi M Mansour

Abstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Dry Powder Inhalers for Delivery of Synthetic Biomolecules.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wafaa AlabsiDepartment of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.
Maria F AcostaSkaggs Pharmaceutical Sciences Center, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.
Fahad A Al-ObeidiDepartment of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.
Meredith HayThe BIO5 Institute, The University of Arizona, Tucson, AZ 85721, USA.
Robin PoltDepartment of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.
Heidi M MansourSkaggs Pharmaceutical Sciences Center, College of Pharmacy, The University of Arizona, Tucson, AZ 85721, USA.ORCID 0000-0003-3993-9210

Funding

NHLBI NIH HHS P01 HL103453NHLBI NIH HHS R01 HL137282NIAID NIH HHS R21 AI135935NIA NIH HHS R21 AG054766NIA NIH HHS R43 AG069524NIA NIH HHS U01 AG066623NIDA NIH HHS UG3 DA047717NIH HHS 5UG3DA047717 U01AG066623 R01HL137282NIH HHS R21AG054766 R21AI135935 P01HL103453
6 · The paper itself

Abstract

The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally. Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases. The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration. We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders. Solid phase peptide synthesis (SPPS) successfully produced Ang (1-7) and PNA5. Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic. Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose. The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (T

Indexed as

air–liquid interfaceALIangiotensinbraincell viabilityglycopeptidein vitro 2D/3D cell culturepartitioningsolid phase peptide synthesissolubilitySPPSTEERtransepithelial electrical resistance

Identifiers

PMID34452239
PMCPMC8398878

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.